Kayzoni 200mg Capsule 60`S

Descripción

 Introduction

Kayzoni is a kinase inhibitor used to treat patients with ALK or ros1-positive metastatic non-small cell lung cancer (NSCLC).

 Warning & Precautions

●Hepatotoxicity: fatal hepatotoxicity occurred in 0.1% of patients. Monitor the liver regularly. Pause, reduce, or permanently terminate Kayzoni.

●Interstitial lung disease (ILD)/pneumonia: 2.9% of patients. Patients with ILD/ pneumonia are permanently discontinued.

●Prolonged QT interval: 2.1% of patients.

Electrocardiograms and electrolytes were closely monitored in patients who had a history or tendency to extend QTc, or who were taking medications that might extend the QT interval. Pause, reduce, or permanently terminate Kayzoni.

●Bradycardia: Kayzoni may cause bradycardia. Monitor your heart rate and blood pressure regularly. Suspend, reduce, or permanently terminate Kayzoni.

●Severe impairment of force: approximately 0.2% of patients were reported. Conduct an ophthalmic evaluation. Discontinue use of this drug in severely impaired patients

●Embryo toxicity: may cause fetal damage. Effective contraceptive measures are recommended to avoid potential fetal risks.

 How to Use

1. Therapy period

● Recommended dosage: 250mg, taken orally, 2 times daily.

● Renal injury: for patients with severe renal injury (creatinine clearance rate <30mL/min) without dialysis, oral administration of 250mg once a day is recommended. 2. Dosage form specification ●Capsule, 250mg, 200mg. 3. Contraindications

 Side Effects

Common

 More Information

Storage

 Disclaimer:

The contents of this website are for informational purposes only and not intended to be a substitute for professional medical advice, diagnosis, or treatment. Please seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition. Do not disregard professional medical advice or delay in seeking it because of something you have read on this website.